Compare Sanofi SA (SNY) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Sanofi SA trades at $43.12 (market cap $103.41B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $73.05. The key difference: Sanofi SA pays a 5.65% dividend while Vanguard Tax Managed Fund FTSE Developed Markets ETF pays none, and Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| SNY | VEA | |
|---|---|---|
Market Cap | $103.41B | — |
Sector | Health | — |
52-Week High | $52.34 | $73.79 |
52-Week Low | $41.33 | $58.90 |
Enterprise Value | $123.44B | — |
Dividend Yield | 5.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
VEA trades at $73.46, down 0.41% on the day, with a bullish technical outlook supported by moving averages. The ETF recently hit a 52-week high of $74.04, indicating strong momentum. Institutional interest is growing, with multiple firms increasing positions in Q2 2026. VEA offers exposure to developed international markets with a low 0.03% expense ratio, making it a cost-effective diversification tool compared to broader international or emerging market ETFs.
The outlook remains positive given institutional accumulation and technical strength, though risks include currency fluctuations and global economic sensitivity. VEA's focus on developed markets provides stability versus emerging markets, but investors should monitor international economic trends that could impact performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
